资讯

Nasdaq5 年
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication ... - Nasdaq
Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved its supplemental New Drug Application for EUCRISA ® ointment, 2%, extending the lower age limit from 24 months ...
Monthly Prescribing Reference8 年
Eucrisa Gains FDA Approval for Atopic Dermatitis - MPR
The Food and Drug Administration (FDA) has approved Eucrisa ... Eucrisa will be available as a 2% ointment. For more information call (650) 543-7500 or visit Pfizer.com.
Monthly Prescribing Reference5 年
Eucrisa Approved for Children as Young as 3 Months With Atopic Dermatitis - MPR
Credit: Pfizer. Eucrisa (crisaborole) ointment, 2%, is now approved for the treatment of mild to moderate atopic dermatitis in pediatric patients as young as 3 months old. Eucrisa (crisaborole ...
Nasdaq5 年
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants
Pfizer Inc. PFE announced that the FDA has approved a supplemental new drug application (sNDA) for its eczema drug, Eucrisa (crisaborole) ointment, 2%. The sNDA sought label expansion of Eucrisa ...
Yahoo Finance5 年
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants - Yahoo Finance
Pfizer Inc. PFE announced that the FDA has approved a supplemental new drug application (sNDA) for its eczema drug, Eucrisa (crisaborole) ointment, 2%. The sNDA sought label expansion of Eucrisa for ...
Yahoo Finance5 年
Pfizer's Eczema Drug Eucrisa Gets FDA Approval for Infants - Yahoo Finance
Pfizer Inc. PFE announced that the FDA has approved a supplemental new drug application (sNDA) for its eczema drug, Eucrisa (crisaborole) ointment, 2%. The sNDA sought label expansion of Eucrisa ...
Business Insider6 年
EUCRISA™ (crisaborole) Now Available in Canada - Markets Insider
EUCRISA™ is a new, steroid-free, topical ointment for mild to moderate atopic dermatitis (eczema) 1 First prescription treatment indicated for mild to moderate AD to be approved in more than 10 ...
Business Insider3 年
Padagis Confirms First-to-File Patent Challenge For Generic Version Of Eucrisa®
ALLEGAN, Mich., Sept. 28, 2021 /PRNewswire/ -- Padagis announced today that Anacor Pharmaceuticals, Inc initiated patent litigation on September 24, 2021 in the U.S. District Court for the ...
Yahoo Style UK6 年
Pfizer's Eucrisa Proves Safety in Kids with Atopic Dermatitis - Yahoo Life UK
Pfizer Inc. PFE announced top-line results from a late-stage study, which evaluated its PDE4 inhibitor, Eucrisa (crisaborole ointment, 2%), for the treatment of mild to moderate atopic dermatitis (AD) ...
WebMD1 年
What Are PDE-4 Inhibitors for Atopic Dermatitis? - WebMD
The FDA has so far approved one topical PDE-4 inhibitor, crisaborole (Eucrisa) for atopic dermatitis. It’s available as an ointment in a 2% concentration. The ointment not only delivers the ...
Mena FN3 年
Padagis Confirms First-to-File Patent Challenge For Generic Version Of Eucrisa® - MENAFN.COM
ALLEGAN, Mich., Sept. 28, 2021 /PRNewswire/ -- Padagis announced today that Anacor Pharmaceuticals, Inc initiated patent litigation on September 24, ...